Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
|Videos|August 22, 2022
Cannabis: Separating the Conversation on CBD and THC
Author(s)John J. Miller, MD
CBD and THC? What's the difference and why does it matter?
Advertisement
John J. Miller, MD, shares why it is important to differentiate between CBD and THC when discussing cannabis at the
Dr Miller is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief, Psychiatric Times™; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; Consulting Psychiatrist, Exeter Hospital, Exeter; Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5